REPROGRAMMING THE IMMUNE SYSTEM

WHAT WE DO

ACHIEVING IMMUNE TOLERANCE

First-in-class therapies designed to reprogram the immune system to achieve antigen-specific tolerance for immune-mediated disease

BROAD POTENTIAL IMPACT

Clinically validated platform with applications across a wide range of immune-mediated disease
“To our knowledge, this is the first clinical trial to demonstrate induction of antigen specific immune tolerance in any autoimmune disease”
-Ciaran Kelly, M.D., Professor of Medicine at Harvard Medical School and Director of the Celiac Center at Beth Israel Deaconess Medical Center

GOLD STANDARD IN IMMUNE TOLERANCE

OUR TECHNOLOGY

COUR’s platform of immune-modifying nanoparticles treats the root cause of immune-mediated disease unlike traditional approaches, which rely on toxic immune suppressants or avoidance strategies.
COUR Nanoparticle Platform
For autoimmune and allergic conditions
This approach to immune tolerance is based on decades of research by Stephen D. Miller, Ph.D. at Northwestern University

The nanoparticle surface is functionalized to enhance immune uptake. The interior core is loaded with disease-specific antigen or allergen.

OUR PIPELINE AND PROGRAMS

UNMATCHED BREAKTHROUGH

COUR’s CNP-101 for celiac disease, partnered with Takeda, is the first therapy to induce antigen-specific immune tolerance in any autoimmune disease in humans.

VALIDATED PLATFORM WITH BROAD APPLICATIONS

COUR’s Nanoparticle Platform (CNP) can be employed to induce disease-specific tolerance for the treatment of a myriad of autoimmune and allergic diseases by changing the antigen or allergen encapsulated within the nanoparticle.
With clinical validation from its lead therapeutic program, CNP-101 in celiac disease, COUR is advancing its pipeline of first-in-class therapies for immune-mediated disease.

IMMUNE REPROGRAMMING

CELIAC DISEASE (CNP-101)
PEANUT ALLERGY (CNP-201)
MULTIPLE SCLEROSIS (CNP-202)
NEUROMYELITIS OPTICA (CNP-Aquaporin 4)
NEUTRALIZING ANTIBODIES (CNP-AAVc)

WHO WE ARE

We are a group of dedicated scientific, medical, and business professionals who are driven to find treatments and cures to immune-mediated diseases. By focusing our research at the root cause of disease, we seek to provide treatments previously unavailable to doctors and their patients.

OUR ECOSYSTEM